MSD’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants October 01, 2024 MSD Completes Acquisition of Investigational B-Cell Depletion Th...
Pharma Pharmaceutical researchers and manufacturers must be able to guarantee the safety and efficacy of their formulations through pervasive structural analysis at multiple points in the research and development (...